Synthetic biology company Intrexon sets terms for $125 million IPO

By
A A A

Intrexon, which is developing synthetic biology technologies, announced terms for its IPO on Monday. The Germantown, MD-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Intrexon would command a fully diluted market value of $1.4 billion.

Intrexon, which was founded in 1998 and booked $16 million in sales for the 12 months ended March 31, 2013, plans to list on the NYSE under the symbol XON. Intrexon initially filed confidentially on May 10, 2013. J.P. Morgan and Barclays are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: XON

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Your Car Is Spying on You
Your Car Is Spying on You           

Stocks

Referenced

50%

Most Active by Volume

73,078,214
  • $30.33 ▼ 3.90%
57,046,796
  • $15.52 ▲ 0.45%
51,290,831
  • $100.57 ▲ 0.04%
39,855,468
  • $8.13 ▲ 1.37%
31,693,544
  • $5.50 ▲ 20.35%
31,532,510
  • $10.33 ▲ 0.78%
31,526,753
  • $39.10 ▲ 47.21%
28,366,542
  • $26.36 ▲ 1.19%
As of 8/20/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com